Research Study Opportunity:

Adults with Relapsing Forms of Multiple Sclerosis (RMS)

The purpose of the study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide.

Who can take part in the study?

You, or someone you care for, may be able to take part if you/they:

- Are 18-55 years old
- Have a previous diagnosis of RRMS
- Have an EDSS score ≤5.5 at the first visit (screening visit)
- Have at least 1 of the following prior to screening:
  - ≥1 documented relapse within the previous year OR
  - ≥2 documented relapses within the previous 2 years, OR
  - ≥1 documented Gd enhancing lesion on an MRI scan within the previous year.

Additional Study Details

- This study will have variable duration of approximately 40 months for the first participant and approximately 20 months for the last participant randomized.
- Scheduled visits will include 1 common end of study visit and 3 follow-up visits; visit frequency is every 4 weeks for the first 6 months and then every 3 months.
- Participants will receive a stipend for each visit as well as travel reimbursement.

Study Location:

Minnesota Center for
Multiple Sclerosis

15700 37th Ave N, Suite 110
Plymouth, MN 55446